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Purpose. To develop a new minimal-stress model for intranasal administration in freely moving rats and
to evaluate in this model the brain distribution of acetaminophen following intranasal versus intravenous
administration.
Methods. Male Wistar rats received one intranasal cannula, an intra-cerebral microdialysis probe, and
two blood cannulas for drug administration and serial blood sampling respectively. To evaluate this novel
model, the following experiments were conducted. 1) Evans Blue was administered to verify the
selectivity of intranasal exposure. 2) During a 1 min infusion 10, 20, or 40 μl saline was administered
intranasally or 250 µl intravenously. Corticosterone plasma concentrations over time were compared as
biomarkers for stress. 3) 200 µg of the model drug acetaminophen was given in identical setup and
plasma, and brain pharmacokinetics were determined.
Results. In 96% of the rats, only the targeted nasal cavity was deeply colored. Corticosterone plasma
concentrations were not inﬂuenced, neither by route nor volume of administration. Pharmacokinetics of
acetaminophen were identical after intravenous and intranasal administration, although the Cmax in
microdialysates was reached a little earlier following intravenous administration.
Conclusion. A new minimal-stress model for intranasal administration in freely moving rats has been
successfully developed and allows direct comparison with intravenous administration.
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INTRODUCTION
Targeting the central nervous system (CNS) by intranasal
delivery is a promising alternative for oral or parenteral
administration, and is investigated to directly target the brain,
thereby increasing CNS target site bioavailability and the
efﬁcacy of CNS drugs (1–3). Little is known however on
the distribution of CNS drugs into the target site, i.e. the
extracellular ﬂuid (ECF) surrounding the pharmacologic
receptors in brain tissue, following intranasal administration.
Current pharmacokinetic-pharmacodynamic (PK-PD)
studies after intranasal administration in small laboratory
animals are performed with anaesthetized animals, whether
or not in combination with complete isolation of the nasal
cavity and a cannulated trachea to aid breathing (4–7). Other
research is based upon restrained animals(8). All methods
currently used have major inﬂuence on physiology (i.e. blood
ﬂow, nasal immunology, mucociliary clearance, nasal cycle,
airﬂow dynamics, and stress), which all play important roles
in the PK and/or PD of compounds (9–17). Therefore, this
methodology complicates quantiﬁcation of PK-PD endpoints
and consequently the extrapolation to the in-vivo human
situation.
To meet the demands for animal PK/biomarker models
and nasal administration techniques, which allow better
interpretation and translation of PK-PD parameters from
animal to man, a new animal model is needed that allows
drug administration under minimal stress conditions in freely
moving animals.
The objective of this study was to develop and validate a
new preclinical, reﬁned minimal stress animal model, in which
we can administer compounds intranasally and intravenously,
while blood- and brain ECF samples can be taken over time,
to obtain PK-PD parameters in plasma and brain of freely
moving animals. After comparing the size of nasal cavities,
the highly vascular olfactory epithelium ratios, and cost-
considerations of eight different species, as described by
Ugwoke et al. (17), we focused on the rat as animal of choice.
An intranasal cannula was manufactured and implanted
together with an intracerebral microdialysis probe. Also the
animals received two blood cannulas for drug administration
and serial blood sampling respectively. The intranasal site of
administration needed to be substantiated by a staining study.
Through corticosterone measurements and comparison with
literature, any stress effects during our experimental- and
administration techniques had to be excluded (18). Then, our
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model had to be validated, which was done by the adminis-
tration of a model compound and comparing the pharmaco-
kinetics between the groups. Acetaminophen was used for
its linear plasma and BBB transport kinetics (19–23). P-
glycoprotein (P-gp) efﬂux did not have to be considered since
acetaminophen is no P-gp substrate (20–22). To explain
concentration time proﬁles and include both intraindividual
and interindividual variability, pharmacokinetic modelling
was used to calculate population parameter estimates of
blood- and brain PK.
MATERIALS AND METHODS
Surgery and Methods
All animal procedures were performed in accordance
with Dutch laws on animal experimentation. The study
protocol was approved by the Animal Ethics Committee of
Leiden University (UDEC nr. 6023 and 6132). Male Wistar
WU rats (245±18 g, Charles River, The Netherlands), n=89,
were housed in groups for 7–13 days (Animal Facilities,
Gorlaeus Laboratoria, Leiden, The Netherlands), under
standard environmental conditions (Ambient temperature
21°C; humidity 60%; 12/12 h light, background noise, daily
handled), with ad libitum access to food (Laboratory chow,
Hope Farms, Woerden, The Netherlands) and acidiﬁed water.
Between surgery and experiments, the animals were kept
individually in Makrolon type three cages for 7 days to
recover from the surgical procedures.
All surgical procedures were performed under complete
anesthesia with subcutaneous administration of 0.1 ml/100 g
Ketanest (ketamine base 25 mg/ml, Pﬁzer B.V., Capelle a/d
Ijssel, the Netherlands), and 0.01–0.017 ml/100 g Domitor
(medetomidine hydrochloride 1 mg/ml, Pﬁzer Animal Health
B.V. Capelle a/d Ijssel, The Netherlands). Body temperature
was maintained at 37°C by an electric heating pad. All
cannulas were disinfected with 0.1% benzalkoniumchloride.
The animals were chronically instrumented with a CMA/
12 microdialysis guide (Aurora Borealis Control, Schoone-
beek, The Netherlands) in the olfactory bulb. The guide was
inserted at 53º from the dorsoventral axis (towards posterior)
parallel to the sagittal plane, at the coordinates AP −2.5 mm,
L −0.9 mm, V −6.4 mm from bregma. The intranasal probe
was manufactured (Fig. 1) by bending the sawn off tip of a 27
gauge needle (90°) and glueing the blunt end to 10 cm tubing
(Portex Fine Bore polythene tubing, Smiths Industries, Kent
England). With a 1.0 mm drill, a hole was drilled through the
nasal bone (AP 12 mm and L -0.5 mm), the metal tip was
pressed into the hole and attached with histo-acryl (B. Braun
Medical B.V., Oss, The Netherlands). The nasal cannula was
tunneled subcutaneously to the back of the head. The end
was melted shut to prevent infection. Consequently, the
animals received two cannulas. To obtain blood samples,
3 cm of ID 0.28 mm cannula (SIMS Portex LTD, England)
was inserted in the femoral artery, connected to 16 cm x
0.58 mm internal diameter (ID) cannula (Portex Fine Bore
polythene tubing Smiths Industries, Kent England,). For drug
administration, 4 cm of ID 0.58 mm cannula was inserted in
the femoral vein, and 16 cm of ID 0.58 mm cannula was,
similar to the sampling cannula, led subcutaneously to the
back of the head where it was ﬁxated with a rubber ring.
After the surgery the animals received 0.03 ml Temge-
sic® intramuscular (Schering-Plough, The Netherlands) and
0.3 ml Ampicillan® (Alfasan B.V. Woerden) subcutaneously.
After 6 days the guide was replaced by the microdialysis
probe (CMA/12, 4 mm Polycarbonate membrane, cut-off
20 kD) at a pre-experiment interval of 24±1 h.
In the corticosterone study, a control group of seven rats
received 500 µl intravenously administered saline (B. Braun
Melsungen AG, Melsungen, Germany) during a 1-minute
infusion with an automated pump (Harvard apparatus 22,
model 55–2222, Holliston, MA, USA). The experimental
groups received 10, 20, or 40 µl of saline intranasally (n=8, 10,
and 9 respectively). Blood samples of 200 μl were taken from
the arterial cannula at t=0 (blank), 5, 10, 20, 35, 60, 90, 120,
150, and 180 min, shaken in heparin (10 IE) coated
eppendorfcups (Sarstedt, Nümbrecht, Germany), and tempo-
rarily stored on ice. After the experiment the samples were
centrifuged for 15 min at 5,000 rpm and stored at −20°C.
Using the aforementioned automated pump, in the
acetaminophen study the control group received a dose of
200 µg acetaminophen (Leiden University Medical Center
Pharmacy, Leiden, The Netherlands) in 250 µl saline intrave-
nously in 30 s. In the experimental groups, 200 µg acetamin-
ophen in 20, 30, or 40 µl saline was administered intranasally
during a 1 min infusion. Start and duration of infusion was
corrected for internal volume of the tubing so that infusion
started at t=0 min. Blood samples of 200 μl were taken from
the arterial cannula at t=0 (blank), 5, 10, 20, 35, 60, 90, 120,
150, and 180 min, and temporarily stored in heparin (10 IE)
coated eppendorfcups on ice. After the experiment the
samples were centrifuged for 15 min at 5,000 rpm and stored
at −20˚C.
Microdialysis perfusion ﬂuid (PF) was prepared (24),
consisting of phosphate buffer (2 mM, pH 7.4), containing
145 mM sodium, 2.7 mM potassium, 1.2 mM calcium, 1.0 mM
magnesium, 150 mM chloride, and 0.2 mM ascorbate, which
was ﬁltered, stored in glass vials (−20˚C), and soniﬁed before
use. Tubing (1.2 μl/100 mm FEP-tubing CMA/Microdialysis
AB, Stockholm, Sweden) was connected with tubing adapters
(CMA/Microdialysis, Stockholm, Sweden) to the microdial-
ysis probe’s inlet and outlet. Microdialysis vials were pre-
weighed and placed in a cooled fraction collector (Univentor
820 Microsampler, Antec, Netherlands) to collect the micro-
dialysate samples. Microdialysis probes were continuously
ﬂushed with PF (2 µl/min, Bee-Hive, Bioanalytical Systems
Inc. W-Lafayette, USA), and 10 min interval samples were
collected between t=−1 h to t=1 h, followed by 20 min
Fig. 1. Schematic representation of the intranasal cannula. The
0.28 mm internal diameter, and 0.61 mm outer diameter tubing is
glued to the bended (90º), sawn off tip of a 27 gauge needle.
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interval samples until t=3 h. After sample collection, vials
were weighed to determine true probe perfusion rate (a
maximal deviation of 5% was allowed for the sample to be
included in the data), and stored at −80˚C.
In 27 rats of the intranasal groups, 30 µl 0.5% Evan’s
blue was administered in 30 s at the end of the experiments.
10 to 15 min later, the animals were sacriﬁced with an
overdose of Nembutal (Ceva Sante Animale, Naaldwijk, The
Netherlands). The nose tip, nasal cavities, brain, mouth,
lungs, and intestines were visually examined for blue color-
ation and scored on a scale; 3, 2, 1, and 0, representing full,
medium, light, and no coloration respectively.
Analysis
For the plasma corticosterone (CORT) concentra-
tions, a commercially available 125I-corticosterone Radio
Immunoassay (RIA) was used (ImmunoChem™ Double
Antibody Corticosterone 125I RIA kit, MP Biomedicals,
Orangeburg, NY, USA), according to the instructions of
the manufacturer. Data acquisition was performed on a
Gamma Scintillation Counter (Minaxi 5000 series, Packard).
Concentrations were calculated using R 2.5.0 (The R
Foundation for Statistical Computing, Vienna, Austria). Data
exceeding 1.5 times the interquartile range was excluded from
the dataset. Geometric means of the CORT concentrations
for the control group and all the animals at t=0 was calculated,
and compared with literature to determine the amount of
stress induced by our operational and handling techniques.
Heteroscedasticity was eliminated by calculating logarithmic
conversion of the data (25,26), and data were normalized to
their own baseline to minimize interindividual variability.
Thereafter, the groups were tested at every time point by a
single factor ANOVA to determine the amount of stress
induced by our experimental techniques.
Acetaminophen concentrations in plasma and microdia-
lysate were determined using High Pressure Liquid Chromo-
tography with Electro-Chemical Detection (HPLC-ECD). For
all procedures Puriﬁed Millipore water (MQ, resistivity 18.2
MΩ.cm) from a Milli-Q® PF Plus system was used (Millipore
B.V., Amsterdam, The Netherlands). Sigma, Zwijndrecht, The
Netherlands delivered 3,4-Dihydroxybenzylamine hydrobro-
mide (DHBA), L-cycteine, and 1-octane-sulfonic acid (OSA).
Ethylenediaminetetraacetic acid (EDTA), Perchloric acid,
Sodiumacetate, and L-(+)-Ascorbic acid were obtained from
Baker, Deventer, The Netherlands. Ortho-Phosphoric acid, di-
Sodium hydrogen phosphate dihydrate, and Sodium dihydro-
gen phosphate monohydrate were obtained from Merck,
Amsterdam, The Netherlands. Methanol and Acetic acid from
Biosolve B.V., Valkenswaard, The Netherlands. Calibration
solutions were prepared by adding 50 µl blank plasma to 50 µl
calibration standard; 10, 25, 50, 100, 200, 300, 400, 500, and
1,000 ng/ml acetaminophen in antioxidant (0.1 M Acetic Acid,
3.3 mM L-cysteine, 0.27 M EDTA, 0.0125 mM L-(+)-Ascorbic
acid, S. Sarre, personal communications).
To 50 µl of the plasma samples 50 µl MQ was added. To
these samples 25 µl internal standard (IS), containing 150 ng/
ml DHBA, was added and proteins were precipitated by
adding 100 µl 6% Perchloric acid. After vortexing and
centrifugation (10 min at 4000 rpm), the supernatant was
transferred into a clean glass tube; 150 µl 1 M Sodiumacetate
was added, and after vortexing, injected into the HPLC-ECD.
20 µl of the microdialysate samples was vortexed with 20 µl IS
and directly injected into the HPLC-ECD system.
The analytical equipment consisted of a LC-10 AD pump
(Shimadzu, ‘s Hertogenbosch, The Netherlands), a Waters
717plus Autosampler (Waters, Etten-Leur, The Netherlands),
a pulse damper (Antec Leyden, Zoeterwoude, The Nether-
lands), a C18 ODS Ultrasphere 5 µm column (4.6 mm x
15 cm) with C18 reﬁll guard column (Alltech Netherlands B.
V., Ridderkerk, The Netherlands), an electrochemical amper-
ometric detector (DECADE, software version 3.02, Antec
Leyden B.V., Zoeterwoude, The Netherlands), a VT-03
electrochemical ﬂow cell, 25 µm spacer, and in situ AG/AgCl
(ISAAC) reference electrode (ﬁlled with a saturated potas-
siumchloride solution) operating in DC mode. The mobile
phase (MP) consisted of a 85% Phosphate buffer (96,4%
1.0 M NaH2PO4, 3,6% 1.0 M Na2HPO4, diluted with MQ to
50 mM Phosphate buffer, and OSA was added to obtain
2 mM OSA), 15% MeOH and 100 mg/l EDTA. MP was
ﬁltered through a 0.2 µm nylon ﬁlter membrane (Alltech
Netherlands B.V., Ridderkerk, The Netherlands).
Data acquisition and processing was performed using
Empower® data acquisition software (Waters, Etten-Leur,
The Netherlands). For constructing the calibration curve,
linear regression analysis was applied using weight factor 1/
(y)2. Data exceeding 1.5 times the interquartile range were
excluded from the dataset before plotting geometric mean
concentrations over time. Data analysis, statistical analysis,
and plotting was performed using Microsoft® Ofﬁce Excel
2003 (Microsoft Corporation, USA) and OriginPro® 7.5
(OriginLab Corporation, Northhampton, MA, USA).
Heteroscedasticy was eliminated before executing a
single factor ANOVA on every time point (25,26). When
p<0,05, a Student T-test (one-tailed homoscedastic) was
performed between the individual groups per time point.
Areas Under the Curve (AUC) were calculated by the
trapezoidal rule and microdialysis AUC’s were corrected for
in vitro recovery. AUC’s were plotted, and tested for differ-
ences between groups by single factor ANOVA. The absolute
recovery was calculated by dividing the plasma AUC after IN
administration by the plasma AUC after IV administration.
Nonlinear mixed effect modelling (NONMEM 6.2, run in
the PSN module (27) under Windows XP Professional 2002
(service pack3) on an Intel Pentium D CPU3.2 GHz proces-
sor) was used to model the pharmacokinetic parameters
clearance and volume of distribution. 1-, 2- and 3-compart-
ment models were entered in various subroutines in NON-
MEM for the experiments with acetaminophen, and
identiﬁed by likelyhood ratio test (p<0.05; decrease in
objective function value of 3.84 points), pharmacokinetic
parameter estimate endpoint, and goodness-of-ﬁt plots. The
interindividual variability of the blood PK model was
assumed log-linear and optimized by taking possible correla-
tion between parameters into account, and by testing the
intraindividual variability through an additive error model
versus a constant coefﬁcient of variation model. The individ-
ual parameter estimates of the blood PK model allowed
estimation of intercompartmental clearance and volume of
distribution in the brain compartment. Population parameter
estimates were assumed to be normally distributed, and
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considered equal when the 95% conﬁdence intervals of the
parameter estimates overlap (1.96 times the standard error).
RESULTS
Evan’s Blue
Of the 27 rats that had received Evans Blue through the
intranasal probe in the right nasal cavity, one had a broken
septum and was excluded in the determination of the nasal
coloration. One animal experienced blocking of the intranasal
probe, thereby decreasing the amount of Evan’s Blue reach-
ing the right nasal cavity. Full coloration of the right nasal
cavity was observed in 96% of the animals. The nose tip,
tongue, palate and intestine were light colored in 81%, 89%,
93%, and 79% of the animals respectively. In the left nasal
cavity 67% was not colored. In 96% of the animals the lungs
as well as the olfactory bulb were not colored. Table I shows
all the acquired data.
Corticosterone as Biomarker for Stress
Geometric mean (± S.E.M.) of CORT concentrations in
plasma at t=0 were 166±14 ng/ml (n=33). The groups did not
show signiﬁcant differences (p-values>0.23) over the time
period of 180 min (Fig. 2).
Acetaminophen as Model Compound
The log-normal geometric mean-time proﬁles of the
concentrations in plasma after administration of acetamino-
phen (Fig. 3) showed the same proﬁles for all groups. At t=
10 min there were differences between the groups when
tested IV vs 30 µl, 20 µl vs 30 µl, and 20 µl vs 40 µl (P-values
are 0.04, 0.00, and 0.02 respectively). At t=180 differences
were found between IV and 20 µl, 20 µl vs 30 µl, and 20 µl vs
40 µl (P-values were 0.00, 0.04, and 0.02 respectively). Areas
under the curve (AUC) in plasma with their standard error of
the means were calculated (Fig. 4); 10.5±0.7, 11.6±0.6, 8.8±
0.9, and 9.6±0.8 (µg*min)/ml for IV, 20, 30, and 40 µl IN
administration respectively. No statistically signiﬁcant differ-
ences between the groups were found (P=0.07).
After measuring and plotting the geometric mean (± S.E.
M., Fig. 3) of acetaminophen brain microdialysate concen-
trations over time, single factor ANOVA revealed a differ-
Fig. 2. Concentration-time proﬁles of corticosterone (geometric
mean ± S.E.M.) in plasma after intranasal administration of different
volumes of saline (IN-20, -30, and -40 µl), compared to intravenous
(IV-500 µl) administration. Single factor ANOVA proves no differ-
ences between the groups (p>0.23). n=9, 9, 8, and 6 for the IV, IN-
20 µl, IN-30 µl, and IN-40 µl groups respectively.
Fig. 3. Concentration-time proﬁles (geometric means ± S.E.M.) of
acetaminophen in plasma and brain microdialysate after intranasal
(IN) administration of 200 µg acetaminophen in different volumes,
compared to intravenous (IV) administration. At t=10 min concen-
trations in plasma (solid line) differed when tested IV vs. IN-30 µl,
IN-20 µl vs. IN-30 µl, and IN-20 µl vs. IN-40 µl (p=0.04, 0.00, and 0.02
respectively). At t=180 differences were found between IV and 20 µl,
20 µl vs 30 µl, and 20 µl vs 40 µl (p=0.00, 0.04 and 0.02 respectively).
In the brain microdialysates (dotted line) differences were found at t=
5, 35, and 90 min (p=0.00, 0.04, and 0.03 respectively).
Table I. Colouration of Several Tissues After Intranasal Administration of 30 µl 0.5% Evan’s Blue in 30 s














cavity Esophagus Bowels Stomach Tongue Palate
0 5 26 26 1 2 0 18 6 7 3 3 2
1 22 1 1 26 25 0 4 21 20 23 24 25
2 0 0 0 0 0 1 3 0 0 1 0 0
3 0 0 0 0 0 25 1 0 0 0 0 0
Tissue of 27 rats has been observed for full, medium, light, or no colouration scored by 3, 2, 1, and 0 respectively. The table shows the number
of rats with accompanying scores.
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ence in proﬁles at t=5, 35 and 90 min (P-values were 0.00,
0.04 and 0.03 respectively). The maximal brain microdialysate
acetaminophen concentration was reached earlier after intra-
venous administration. Microdialysis in vitro recovery was
40%. The mean AUCs ± S.E.M. of the brain concentrations
were 2.54±0.31 (µg*min)/ml and 2.55±0.44 (µg*min)/ml for
the control group and experimental group receiving 20 µl
solution respectively and did not differ (Fig. 4, p=0.98). The
absolute recovery of acetaminophen was 95%.
After comparing several models, a 2-compartment model
with the brain compartment as an effect compartment,
constant coefﬁcient of variation for intraindividual variablility
and correlation between the clearance and volume of
distribution of compartment 1 and 3 proved to ﬁt the data
best for both the experimental and the control study.
Estimating interindividual variability on clearance and vol-
ume of distribution in effect compartment 2 did only improve
the model (decrease in objective function value>3.84) of
intranasal administration. Parameter estimates with their
95% conﬁdence interval aquired from NONMEM are listed
in Table II.
DISCUSSION
The aim of this study was to develop and validate a new
preclinical, reﬁned minimal stress animal model, in which we
can administer compounds intranasally and intravenously,
with blood- and brain ECF samples to be taken over time.
Our results indicate that IN administration in freely moving
rats does not induce stress, while for the model compound
acetaminophen it was observed that the pharmacokinetics
following IN and IV administration were similar.
Evan’s Blue
Evan’s Blue is a dye with a high afﬁnity for albumin
which is present in nasal mucosa. Besides the expected full
colouration of the targeted nasal cavity, 93% of the animals
showed light coloration of the palate caused by leakage
through the nasopalatine duct that connects the nose and
mouth. This might be an indication for buccal absorption in
rats. which should be considered in the PK and extrapolation
of data to clinical situations, since in humans the nasopalatine
duct does not extend to the mouth. However, due to its role,
in cooperation with the vomeronasal organ, in food recogni-
tion, sex recognition, and courtship we found it not advisable
to close the nasopalatine duct (28). Also, after the 10 min
following Evans Blue administration a small part was
swallowed, which could indicate the possibility of partial oral
uptake after intranasal administration. This can be caused by
passive leakage to the oesophagus and/or active sweeping by
the cilia in the nose. Since rats are obligate nose breathers
(29) this obviously cannot be prevented in freely moving
animals. The concentration-time curves of acetaminophen
however, excluded substantial uptake of compound through
oral absorption. Use of other (more viscous) formulations
could possibly eliminate this problem in future research.
Table II. Population Model Parameter Values
Blood and peripheral pharmacokinetic mode Brain pharmacokinetic model
CL1 (L/h) V1 (L) CL2 (L/h) V2 (L) KA (mg/h) Q3 (L/h) V3 (ml)
θ IV 0.86±0.12 0.19±0.05 0.27±0.21 0.07±0.02* 8.32±5.3 1050±300
IN 0.89±0.11 0.17±0.04 0.40±0.06 0.13±0.03 86.3±19.4 2.63±1.96 886±286
η2 IV 0.03±0.03 0.07±0.06 – – – 0.62±0.53 0.16±0.12
IN 0.09±0.07 0.31±0.21 – 0.16±0.15 – 0.88±1.20 0.19±0.22
ε2 IV 0.01±0.005 0.05±0.02
IN 0.02±0.01 0.06±0.04
Data represented are population parameter estimates (θ) with their interindividual variability (η2 ) and the population intraindividual
variability (ε2 ) with their 95% conﬁdence interval after intravenous (IV) or intranasal (IN) administration of 200 mg acetaminophen.
Parameters of the ﬁrst central compartment are clearance (CL1) and volume of distribution (V1). For the second peripheral compartment
clearance (CL2) and volume of distribution (V2) were determined, as well as the absorption rate constant (KA) after IN administration. In the
brain the intercompartmental clearance(Q) and volume of distribution (V3) were estimated. Parameter estimates that differ between the
studies are denoted with *
Fig. 4. Boxplots of the Area’s Under the Curve (AUC) of
acetaminophen concentration-time proﬁles in plasma (p) and brain
microdialysate(b), following intranasal (IN) administration of 200 µg
acetaminophen in different volumes (-20, -30, and -40 µl), compared
to intravenous (IV) administration. No differences between plasma
AUC’s were found (p>0.07). The AUC’s of the brain microdialysates
also show no difference (p=0.98).
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Corticosterone
In our study, the CORT data show no inﬂuence of
administration techniques, nor of volume of administration.
Cano et al. (18) performed a circadian rhythm study
concerning the CORT concentrations in Wistar rats during
high-fat induced stress and compared it to a normally fed
control group. In that study, plasma concentrations of CORT
were found to be 283±35 ng/ml (means ± S.E.M.) in the
control group, with an amplitude of 97±11 ng/ml, versus 456±
42 ng/ml in the experimental group, showing a signiﬁcant
difference compared to the control group (p<0.01). Also, in
that study, CORT concentrations were roughly 200 ng/ml
straight after onset of the light phase, indicating higher basal
concentrations when compared with our experiments 166±
14 ng/ml (basal average ± S.E.M.). Additionally, Perello et al.
(30) discovered in individually housed Wistar rats, after
decapitation under conditions of minimal stress after the
onset of the light phase, basal concentrations of 363±35 ng/ml
(means ± S.E.M.) in animals. This was signiﬁcantly higher
when compared to their group-housed animals (206±32) and
to our individually housed freely moving animals. Perello et
al. (30) stated their CORT concentrations to be low when
compared to restraining studies and bacterial lipopolysaccha-
ride injection. In our freely moving animals, we ﬁnd no
evidence that stress levels are increased due to our handling
techniques or experiments, moreover, when compared to
aforementioned studies, we have less CORT release indicat-
ing less stress.
Acetaminophen
In principle, differences in the concentration time
proﬁles in both plasma and brain data can be explained by
the absorption phase over the nasal epithelium versus IV
administration, as well as by the difference in infusion time.
Equal plasma AUCs indicate that the same amount of drug as
IV is absorbed after IN administration. Althought differences
are found when testing data per time point, the comparison of
the concentration-time proﬁles with NONMEM show no
differences in parameter estimates, except for V2. Adding
interindividual variability for V2 in the IV model did not
increase the predictability and was therefore left out of the
model, but this can cause the difference in the population
estimates for V2 since adding interindividual variability did
improve the IN model. The individual- and population
estimates described the data well. We can consider the free
drug concentrations in the ECF in terms of intercompart-
mental clearance (Q3) and V3, which gives us information on
the blood-brain-barrier transport and whether direct trans-
port from the nasal epithelium into the brain could be an
issue. Since the plasma pharmacokinetics after IV and IN
administration are similar, increased CNS target site bioavail-
ability after IN administration should result in increased brain
concentrations after IN administration compared to IV
administration, which is not the case.
Acetaminophen is subject to metabolization by P450,
that is highly present in the nasal epithelium (31), but this did
not inﬂuence the PK of acetaminophen following intranasal
administration relative to that following intravenous dosing.
Furthermore, we found no evidence of substantial buccal or
oral absorption in the concentration-time proﬁles of acet-
aminophen. The population estimates of the brain showed no
differences in intercompartmental clearance, volume of
distribution, interindividual- or intraindividual variability.
CONCLUSIONS
The animals showed clear coloration in the right nasal
cavity, so after intranasal administration, the major part of the
administered 30 µl Evan’s Blue remained in the nasal cavity
and the cannula can be used to administer compounds in the
right nasal cavity in freely moving animals, with little or no
drainage to other absorption sites.
When compared to other studies reported in literature,
our experimental and handling techniques resulted in lower
CORT concentrations, which indicates less stress during the
experiments in freely moving animals. The intranasal admin-
istration did not increase CORT concentrations, and there
were no differences in CORTconcentrations when volumes up
to 40 µl are administered, compared to IV administration.
With respect to the plasma and brain pharmacokinetics
of acetaminophen we conclude that following IN administra-
tion no evidence was found for selective distribution
enhancement to the brain. The administration of acetamino-
phen is site speciﬁc, as also concluded from the Evan’s Blue
study. We do emphasize however that the administration of
acetaminophen by the intranasal route shows a very rapid
absorption indicated by identical PK when compared to IV
administration.
In summary, the new intranasal administration method in
freely moving animals allows the local, stress free adminis-
tration of acetaminophen, while blood and brain pharmaco-
kinetics can be observed over time.
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